Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects

European Journal of Pharmacology

Volumn 689, Issue 1-3, 2012, Pages 25-30

  Stathis, Marigo ^a   Pietra, Claudio ^b   Rojas, Camilo ^a   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Helsinn Healthcare (CP)   (Switzerland)

Author keywords

Chemotherapy induced nausea and vomiting; Netupitant; Palonosetron; Substance P

Indexed keywords

CALCIUM ION; GRANISETRON; NETUPITANT; ONDANSETRON; PALONOSETRON; SEROTONIN 3 RECEPTOR; SUBSTANCE P;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; MOLECULAR INTERACTION; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; DRUG SYNERGISM; ISOQUINOLINES; PYRIDINES; QUINUCLIDINES; RECEPTORS, NEUROKININ-1; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SUBSTANCE P;

EID: 84864278359     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.05.037     Document Type: Article

References (27)

1. M.S. Aapro, S.M. Grunberg, G.M. Manikhas, G. Olivares, T. Suarez, S.A. Tjulandin, L.F. Bertoli, F. Yunus, B. Morrica, F. Lordick, and A. Macciocchi A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Oncol. 17 2006 1441 1449 (Pubitemid 44400384)
2. E. Basch, A.A. Prestrud, P.J. Hesketh, M.G. Kris, P.C. Feyer, M.R. Somerfield, M. Chesney, R.A. Clark-Snow, A.M. Flaherty, B. Freundlich, G. Morrow, K.V. Rao, R.N. Schwartz, and G.H. Lyman Antiemetics: american society of clinical oncology clinical practice guideline update J. Clin. Oncol. 29 2011 4189 4198
3. A.A. Borisy, P.J. Elliott, N.W. Hurst, M.S. Lee, J. Lehar, E.R. Price, G. Serbedzija, G.R. Zimmermann, M.A. Foley, B.R. Stockwell, and C.T. Keith Systematic discovery of multicomponent therapeutics Proc. Natl. Acad. Sci. USA 100 2003 7977 7982 (Pubitemid 36760080)
4. N.A. Darmani, and A.P. Ray Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting Chem. Rev. 109 2009 3158 3199
5. N.A. Darmani, S. Chebolu, B. Amos, and T. Alkam Synergistic antiemetic interactions between serotonergic 5-HT(3) and tachykininergic NK(1)-receptor antagonists in the least shrew (Cryptotis parva) Pharmacol. Biochem. Behav. 99 2011 573 579
6. P. Eisenberg, J. Figueroa-Vadillo, R. Zamora, V. Charu, J. Hajdenberg, A. Cartmell, A. Macciocchi, and S. Grunberg Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron Cancer 98 2003 2473 2482 (Pubitemid 37466663)
7. M.B. Emerit, M. Riad, C.M. Fattaccini, and M. Hamon Characteristics of [14C] guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P J. Neurochem. 60 1993 2059 2067 (Pubitemid 23148777)
8. Ettinger, D.S.; Armstrong, D.K.; Barbour, S.; Berger, M.J.P.J.B.; Bradbury, B.; Ellis, G.; Kirkegaard, S.; Kloth, D.D.; Kris, M.G.; Lim, D.; Boehnke Michaud, L.; Nabati, L.; Noonan, K.; Rugo, H.S.; Siler, D.; Sorscher, S.M.; Stelts, S.; Stucky-Marshall, L.; Todaro, B.; Urba, S.; 2011. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM) Antiemesis, version 1.2012. NCCN.org.
9. P. Feyer, and K. Jordan Update and new trends in antiemetic therapy: the continuing need for novel therapies Ann. Oncol. 22 2011 30 38
10. S.L. Freeman, J. Glatzle, C.S. Robin, M. Valdellon, C. Sternini, J.W. Sharp, and H.E. Raybould Ligand-induced 5-HT3 receptor internalization in enteric neurons in rat ileum Gastroenterology 131 2006 97 107 (Pubitemid 44040915)
11. R. Gralla, M. Lichinitser, S. Van Der Vegt, H. Sleeboom, J. Mezger, C. Peschel, G. Tonini, R. Labianca, A. Macciocchi, and M. Aapro Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron Ann. Oncol. 14 2003 1570 1577 (Pubitemid 37304615)
12. N. Guetg, S. Abdel Aziz, N. Holbro, R. Turecek, T. Rose, R. Seddik, M. Gassmann, S. Moes, P. Jenoe, T.G. Oertner, E. Casanova, and B. Bettler NMDA receptor-dependent GABAB receptor internalization via CaMKII phosphorylation of serine 867 in GABAB1 Proc. Natl. Acad. Sci. USA 107 2010 13924 13929
13. P.J. Hesketh, S. Van Belle, M. Aapro, F.D. Tattersall, R.J. Naylor, R. Hargreaves, A.D. Carides, J.K. Evans, and K.J. Horgan Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists Eur. J. Cancer 39 2003 1074 1080 (Pubitemid 36555864)
14. W.P. Hu, X.H. You, B.C. Guan, L.Q. Ru, J.G. Chen, and Z.W. Li Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons Neurosci. Lett. 365 2004 147 152
15. S. Li, B. Zhang, and N. Zhang Network target for screening synergistic drug combinations with application to traditional Chinese medicine BMC Syst. Biol. 5 Suppl 1 2011 S10
16. F. Longo, G. Mansueto, V. Lapadula, R. De Sanctis, S. Quadrini, R. Grande, B. Gori, A. Altavilla, I. D'Antoni, E. Del Signore, L. Stumbo, C. De Luca, B. Cimadon, E. Cortesi, T. Gamucci, and M. Di Seri Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy Support. Care Cancer 19 2010 1159 1164
17. M. Minami, T. Endo, H. Yokota, T. Ogawa, M. Nemoto, N. Hamaue, M. Hirafuji, M. Yoshioka, A. Nagahisa, and P.L. Andrews Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors Eur. J. Pharmacol. 428 2001 215 220 (Pubitemid 33000143)
18. T.H. Oo, and P.J. Hesketh Further improvement in the control of chemotherapy-induced nausea and vomiting: future directions P.J. Hesketh, Management of Nausea and Vomiting in Cancer and Cancer Treatment 2005 Jones and Bartlett Publishers, Inc London 231 245
19. K.T. Papazisis, T.G. Kalemi, D. Zambouli, G.D. Geromichalos, A.F. Lambropoulos, A. Kotsis, L.L. Boutis, and A.H. Kortsaris Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro Cancer Lett. 233 2006 255 264 (Pubitemid 43327381)
20. L. Quartara, and C.A. Maggi The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation Neuropeptides 31 1997 537 563 (Pubitemid 28037471)
21. G. Reiser, and B. Hamprecht Substance P and serotonin act synergistically to activate a cation permeability in a neuronal cell line Brain Res. 479 1989 40 48 (Pubitemid 19030911)
22. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, L.H. Einhorn, E. Ballatori, E. Bria, R.A. Clark-Snow, B.T. Espersen, P. Feyer, S.M. Grunberg, P.J. Hesketh, K. Jordan, M.G. Kris, E. Maranzano, A. Molassiotis, G. Morrow, I. Olver, B.L. Rapoport, C. Rittenberg, M. Saito, M. Tonato, and D. Warr Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann. Oncol. 21 Suppl 5 2010 v232-243
23. C. Rojas, A.G. Thomas, J. Alt, M. Stathis, J. Zhang, E.B. Rubenstein, S. Sebastiani, S. Cantoreggi, and B.S. Slusher Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function Eur. J. Pharmacol. 626 2010 193 199
24. C. Rojas, Y. Li, J. Zhang, M. Stathis, J. Alt, A.G. Thomas, S. Cantoreggi, S. Sebastiani, C. Pietra, and B.S. Slusher The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo J. Pharmacol. Exp. Ther. 335 2010 362 368
25. M. Saito, K. Aogi, I. Sekine, H. Yoshizawa, Y. Yanagita, H. Sakai, K. Inoue, C. Kitagawa, T. Ogura, and S. Mitsuhashi Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial Lancet Oncol. 10 2009 115 124
26. L. Schwartzberg, J. Jackson, G. Jain, S. Balu, and D. Buchner Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting Expert. Rev. Pharmacoecon. Outcomes Res. 11 2011 481 488
27. H. Seeliger, M. Guba, G.E. Koehl, A. Doenecke, M. Steinbauer, C.J. Bruns, C. Wagner, E. Frank, K.W. Jauch, and E.K. Geissler Blockage of 2-deoxy-d-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy Clin. Cancer Res. 10 2004 1843 1852 (Pubitemid 38435576)